Therapure Biopharma Postpones IPO
Therapure Biopharma has announced that, due to current conditions in capital markets, it would postpone its initial public offering.
The initial public offering (IPO) market has grown cold as global markets have been sliding in 2016, and many companies are choosing to postpone their IPOs for more favorable market conditions. Therapure Biopharma is no exception. The company announced that, due to current conditions in capital markets, it would postpone its offering.
While the company is performing above expectations and investor feedback about the quality of management and the company was very positive, Therapure makes this decision in light of the current market environment, in which no IPOs were concluded in the United States or Canada in January.
The underwriters for the offering are GMP Securities, CIBC World Markets and National Bank Financial.
For some background on the company:
Therapure is a biopharmaceutical company focused on manufacturing complex biologics for its customers and on developing, manufacturing and selling its own blood and plasma-related therapeutic products. Its passion for quality and patient safety underpins everything it does in its three divisions: Therapure Biomanufacturing, an award-winning contract development and manufacturing division; Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA technology to develop a portfolio of plasma-derived pharmaceutical products; and Therapure Innovations, a proprietary therapeutics and platform technologies research and development division.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
